Acute Lymphoblastic Leukemia: Treatment Strategies and Considerations
This OncLive Insights features two oncologists who specialize in the treatment of Acute Lymphoblastic Leukemia (ALL). They discuss risk assessment, approaches to treatment of both Philadelphia chromosome positive (Ph+) and Ph- ALL, the factors they consider when choosing a treatment setting (community or tertiary academic center), use of MRD in ALL, sequencing therapies in the relapsed/refractory setting, and the role of CAR T-cell therapy in this patient population.
Ibrahim Aldoss, MD, and James K. McCloskey, MD, share their thoughts on different stratification measures used to assess risk in pediatric, adolescent, and young adult patients newly diagnosed with ALL.
EP. 2: Approaches to Treatment of Ph+ ALL
A discussion on how to approach the treatment of a pediatric or AYA (adolescent and young adult) patient with ALL (acute lymphoblastic leukemia) who is Philadelphia chromosome positive (Ph+ALL).
EP. 4: Approaches to Treatment of Ph- ALL
Ibrahim Aldoss, MD; and James K. McCloskey, MD, discuss how to approach the treatment of a pediatric or AYA patient with ALL who is Philadelphia chromosome-negative (Ph-).
EP. 5: Choosing a Treatment Setting for Patients With ALL
Drs Aldoss and McCloskey share their thoughts on treating patients with ALL at community centers versus at tertiary, academic medical centers.
EP. 7: Approaches to Treatment After Failure to Achieve MRD Negativity
Insights on how to approach an acute lymphocytic leukemia patient who is MRD positive after induction therapy.
EP. 8: Approaches to Treatment for Relapsed/Refractory ALL
Ibrahim Aldoss, MD and James K. McCloskey, MD describe treatment modalities that can be utilized in treating a pediatric or AYA patient with relapsed / refractory ALL.
EP. 9: Salvage Therapies in R/R ALL, Including CAR T-Cell Therapy
Drs Aldoss and McKloskey describe treatments that can be used in the salvage setting of acute lymphocytic leukemia, including CAR T-cell therapy.
EP. 10: Sequencing Therapies in Relapsed/Refractory ALL
Ibrahim Aldoss, MD, and James K. McCloskey, MD, share thoughts on how to effectively sequence available treatment modalities for acute lymphocytic leukemia in various patient populations.
